(firstQuint)A Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.

1%, in Subjects With Common Facial Acne - W0260-301.

 A multicenter, randomized, double-blind, vehicle-controlled, parallel-group study comparing tazarotene foam with vehicle foam in subjects with acne vulgaris.

 Approximately 742 subjects will be enrolled and randomized to 1 of the 2 study product groups in a 1:1 ratio (tazarotene foam: vehicle foam).

 Subjects will apply tazarotene foam or vehicle foam to the entire face once daily for 12 weeks; study visits will occur at baseline (week 0/day 1) and at weeks 2, 4, 8, and 12.

.

 A Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.

1%, in Subjects With Common Facial Acne - W0260-301@highlight

The purpose of this study is to assess safety and efficacy of a new foam formulation of tazarotene in subjects with acne vulgaris.

